evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,776 questions · 7,311 findings · 959 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,498 · 20.5%GRADE not reported 303 · 4.1%Very low 1,839 · 25.2%Low 1,991 · 27.2%Moderate 1,277 · 17.5%High 403 · 5.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Progression‐free survival (PSF) · newly‐diagnosed EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in progression‐free survival (PSF) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… probably leads to lower any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Reactive gel surfaces on operating tables followed by foam surfaces on ward beds vs alternating pressure (active) air surfaces on operating tables and subsequently on ward beds

Proportion of participants developing a new pressure ulcer · preventing pressure ulcers

Reactive gel surfaces on operating tables followed by foam surfaces… may leads to higher proportion of participants developing a new pressure ulcer compared with alternating pressure (active) air surfaces on operating tables and… (low certainty).

1 finding from 1 review

Reactive gel surfaces on operating tables followed by foam surfaces on ward beds vs alternating pressure (active) air surfaces on operating tables and subsequently on ward beds

Time to pressure ulcer development · preventing pressure ulcers

The review found no eligible studies for this question.

1 finding from 1 review

Reactive gel surfaces on operating tables followed by foam surfaces on ward beds vs alternating pressure (active) air surfaces on operating tables and subsequently on ward beds

Support surface associated patient comfort · preventing pressure ulcers

The review found no eligible studies for this question.

1 finding from 1 review

Reactive gel surfaces on operating tables followed by foam surfaces on ward beds vs alternating pressure (active) air surfaces on operating tables and subsequently on ward beds

Health‐related quality of life · preventing pressure ulcers

The review found no eligible studies for this question.

1 finding from 1 review

Reactive gel surfaces on operating tables followed by foam surfaces on ward beds vs alternating pressure (active) air surfaces on operating tables and subsequently on ward beds

Cost‐effectiveness · preventing pressure ulcers

The review found no eligible studies for this question.

1 finding from 1 review

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Death · kidney transplant recipients

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in death compared with standard dose CNI (moderate certainty).

1 finding from 1 review

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Acute rejection · kidney transplant recipients

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in acute rejection compared with standard dose CNI (moderate certainty).

1 finding from 1 review

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Graft loss · kidney transplant recipients

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in graft loss compared with standard dose CNI (moderate certainty).

1 finding from 1 review

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Adverse events: hypertension · kidney transplant recipients

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: hypertension compared with standard dose CNI (low certainty).

1 finding from 1 review

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Adverse events: CMV infection · kidney transplant recipients

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: CMV infection compared with standard dose CNI (low certainty).

1 finding from 1 review

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Adverse events: malignancy · kidney transplant recipients

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

BPD or death by it prior to 37 weeks' PMA (outcomes collected through first event: death, hospital discharge, hospital transfer, or 120 days after birth) · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in BPD or death by it prior to 37 weeks' PMA (outcomes collected… compared with placebo (high certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

Severe (grade 3 or greater) intraventricular hemorrhage (IVH) on cranial ultrasound ‐ not reported · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in severe IVH (grade 3 or 4) compared with placebo (moderate certainty).

1 finding from 1 review